Sarepta Therapeutics is selling off Arrowhead Pharmaceuticals’ shares to stretch its cash runway, while also inking a share ...

MASLD has become the most common chronic liver disease worldwide. The authors review the features of the disease as well as ...

VOR Biopharma's valuation surged with telitacicept, yet dilution risks and share structure uncertainty maintain volatility.

Key Points GAAP earnings per share of $0.04 exceeded the consensus estimate of negative $0.08 for Q2 2025 No commercial revenue reported; company remains in pre-revenue phase with product launches ...

With concerns over a lack of healthcare housing in the Brass City, a new project plans to add dozens of units to a vacant, ...

All the latest Tottenham Hotspur news as Thomas Frank gears up for the new Premier League season with a defeat to PSG in the ...